Tafenoquine-d3 succinate (Synonyms: WR-238605, WR 238605, WR238605, Tafenoquine; trideuerium-labeled Tafenoquine derivative; Tafenoquine-d3 succinate) |
Catalog No.GB62198 |
Tafenoquine-d3 is a trideuerium-labeled Tafenoquine derivative.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1133378-83-2
Sample solution is provided at 25 µL, 10mM.
Tafenoquine-d3 is a trideuerium-labeled Tafenoquine derivative. Tafenoquine, also known as WR-238605, is an oral active antimalaria drug that is being investigated as a potential treatment for malaria, as well as for malaria prevention. Tafenoquine Shows Activity against Trypanosoma brucei. Tafenoquine targets leishmania respiratory complex III and induces apoptosis. Tafenoquine has a long half-life of approximately 14 days and is generally safe and well tolerated, Malaria remains an important cause of global morbidity and mortality. As antimalarial drug resistance escalates, new safe and effective medications are necessary to prevent and treat malarial infection.
Review for Tafenoquine-d3 succinate
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)Review for Tafenoquine-d3 succinate
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *